Drugs / Allo-QuadCAR01-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07284433 | Jan 2026 → Apr 2029 expected | diffuse large B-cell lymphoma, leukemia | AvenCell Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allo-QuadCAR01-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07284433 ↗ |
| Modality | Cell therapy | “This study is testing Allo-QuadCAR01-T, a new off-the-shelf CAR-T therapy for people with hard-to-treat B-cell cancers.” NCT07284433 ↗ |
| Route | Intravenous | “Single dose IV infusion on Day 1” NCT07284433 ↗ |
| Target | CD19 | “Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20” NCT07284433 ↗ |
| Target | CD20 | “Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20” NCT07284433 ↗ |